FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549	
------------------------	--

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response	0.5								

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Heyman Richard A.  (Last) (First) (Middle)  C/O PMV PHARMACEUTICALS, INC.  8 CLARKE DRIVE, SUITE 3  (Street)  CRANBURY NJ 08512					3. C 05/	2. Issuer Name and Ticker or Trading Symbol PMV Pharmaceuticals, Inc. [ PMVP ]  3. Date of Earliest Transaction (Month/Day/Year) 05/12/2021  4. If Amendment, Date of Original Filed (Month/Day/Year)								Relationship of Reporting Person(s) to Issuer Check all applicable)  X Director 10% Owner Officer (give title below)  Individual or Joint/Group Filing (Check Applicable ne)  X Form filed by One Reporting Person Form filed by More than One Reporting					
(City)	(Si	tate) (	(Zip)			Person													
		Tabl	le I - Non	-Deriv	ative	e Se	curitie	s Ac	quired,	Dis	posed o	of, or Be	neficia	lly C	Owned	l			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)						Execution Date,			Code (	Transaction Disposed Of (D) (Instr. 3, Code (Instr. 5)				nd :	5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	v	Amount	(A) o (D)	r Price	Troposo		tion(s)			(III34I. 4)
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,	4. Transacti Code (Ins				6. Date Ex Expiration (Month/Da	Date		7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		Der	Price of rivative curity str. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Ow For Dire or I (I) (	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisab		xpiration ate	Title	Amount or Number of Shares	1					
Stock Option (right to buy)	\$28.33	05/12/2021			A		5,781		(1)	0.	5/11/2031	Common Stock	5,781	\$	\$0.00	5,781		D	

## **Explanation of Responses:**

 $1. \ Shares \ subject \ to \ the \ option \ vest \ in \ 36 \ equal \ monthly \ installments \ beginning \ on \ June \ 12, \ 2021.$ 

## Remarks:

/s/ Winston Kung, by power of attorney

07/23/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.